AstraZeneca has announced a $2bn investment plan to expand its biomanufacturing presence in the US state of Maryland, aiming ...

Drugmaker AstraZeneca said on Wednesday that its Imfinzi asset has been approved in the US for use alongside standard FLOT ...

AstraZeneca boosts its Harbour BioMed collaboration and invests $2 billion to expand biologics manufacturing and clinical ...

(Reuters) -AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of ...

AstraZeneca (AZN.L, AZN.ST) proposed a $2 billion manufacturing investment in Maryland that will, among other things, ...

AstraZeneca is to invest $2bn ramping up manufacturing facilities in Maryland, America, the blue chip drugs giant said on ...

AstraZeneca is investing $2 billion in manufacturing in Maryland that will support 2,600 jobs, state and company officials ...

The investment is set to expand two facilities on US soil and is part of an overarching $50 billion commitment ...

These plans come as part of AstraZeneca’s planned $50bn US manufacturing investment, which the company announced in July.

AstraZeneca to Expand Manufacturing with $2 Billion Commitment Governor Wes Moore announced on November 21, 2025, that ...

AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...

(Alliance News) - AstraZeneca PLC on Tuesday said Imfinzi has been approved in the US as the first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers.